ClinicalTrials.gg
CompletedNCT02898077Updated Jun 14, 2022Results posted

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

A Phase 3 interventional study of Ramucirumab and Paclitaxel in Gastroesophageal Junction Adenocarcinoma and Gastric Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 32 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-14.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy of the study drug known as ramucirumab in participants with gastric and gastroesophageal cancer.

02

Conditions studied

  • Gastroesophageal Junction Adenocarcinoma
  • Gastric Adenocarcinoma

Keywords

  • Second line
  • Angiogenesis
  • Vascular endothelial growth factor receptor 2
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have an Performance Status (ECOGPS) of 0 or 1 at study entry.
  • Have a histopathologically or confirmed diagnosis of gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • Have disease or locally advanced, unresectable disease.
  • Have at least 1 based on (RECIST), Version 1.1.
  • Have experienced documented objective radiographic or symptomatic disease progression during therapy, or within 4 months after the last dose of first-line therapy with any platinum/fluoropyrimidine doublet for unresectable or metastatic disease.
  • Have adequate organ function.
  • Have urinary protein ≤1+ on dipstick or routine urinalysis.

Exclusion criteria

Exclusion Criteria:

  • Have undergone major surgery within 28 days prior to randomization.
  • Have received any chemotherapy other than platinum and fluoropyrimidine with or without anthracycline for advanced gastric or GEJ adenocarcinoma.
  • Have received any previous systemic therapy (including agents) targeting vascular endothelial growth factor (VEGF) or the VEGF receptor signaling pathways.
  • Have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the 3 months prior to randomization.
  • Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to study entry.
  • Have a history of GI perforation and/or fistulae within 6 months prior to randomization.
  • Have experienced any arterial thromboembolic event within 6 months prior to randomization.
  • Have uncontrolled arterial hypertension (systolic blood pressure ≥160 millimeters of mercury [mmHg] or diastolic blood pressure ≥100 mmHg) despite standard medical management.
  • Have a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to randomization.
  • Have a serious illness or medical condition(s).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
440 participants (actual)

Study arms

  • Experimental
    8 milligram/kilogram (mg/kg) Ramucirumab + 80 mg/square meter (mg/m²) Paclitaxel

    8 mg/kg ramucirumab was administered as an intravenous infusion (IV) on days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on days 1, 8, and 15 of every 28-day cycle. Participants may continue on treatment until discontinuation criteria were met.

    Drug: Ramucirumab · Drug: Paclitaxel

  • Experimental
    Placebo + 80 mg/m² Paclitaxel

    Placebo was administered at a volume equivalent to a dose of 8 mg/kg by IV on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on Days 1, 8, and 15 of a 28-day cycle. Participants may continue on treatment until discontinuation criteria were met.

    Drug: Paclitaxel · Drug: Placebo

Interventions

  • Administered IV

    Also known as: LY3009806

  • Administered IV

  • DrugPlacebo

    Administered IV

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

    Time frame: Randomization to the Date of the First Radiographically Documented Progressive Disease or Death from Any Cause (Up To 30 Months)

  2. Overall Survival (OS)

    OS defined as the time from randomization to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

    Time frame: Randomization to Date of Death from Any Cause (Up To 37 Months)

Secondary outcomes

  1. Time to Progression (TTP)

    TTP was time from the date of randomization to the date of radiographic progression (according to RECIST v.1.1). If a participant died due to any reason without radiographic progression, TTP is censored at the last adequate tumor assessment. Target lesions: Progressive Disease (PD): At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). Non target lesions: PD: Unequivocal progression of existing lesions or the appearance of new lesion(s).

    Time frame: Randomization to the Date of the First Radiographically Documented Progressive Disease (Up To 30 Months)

  2. Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

    ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Randomization to Objective Disease Progression (Up To 30 Months)

  3. Duration of Objective Response (DoR)

    DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Date of Objective Response to the Date of the First Radiographically Documented Progressive Disease or Death Due to Any Cause (Up To 24 Months)

  4. Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms. Least square (LS) mean value of changing from baseline to short-term follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\*Visit and baseline.

    Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)

  5. Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms. LS Mean value of changing from baseline to short-term follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\*Visit and baseline.

    Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)

  6. Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score

    EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. A regression equation defines a utility value for these health states to generate an index score. The possible values for index score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state.

    Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)

  7. Change From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score

    EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. The EQ-5D VAS is used to record a participant's rating for his/her current health-related quality of life state on the day of questionnaire administration and is captured on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)

07

Results

Posted Aug 3, 2021

Participant flow

Participant flow — Overall Study
Milestone8 Milligram/Kilogram (mg/kg) Ramucirumab + 80 mg/Square Meter (mg/m²) PaclitaxelPlacebo + 80 mg/m² Paclitaxel
Started294146
Received at least 1 dose of study drug293145
Completed246123
Not completed4823
Withdrew: Enrolled/randomized, but never treated11
Withdrew: Lost to follow-up43
Withdrew: Physician decision02
Withdrew: Sponsor decision3213
Withdrew: Withdrawal by subject63
Withdrew: Discontinued from treatment but refused follow-up21
Withdrew: Ended extension period30

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

Time frame:
Randomization to the Date of the First Radiographically Documented Progressive Disease or Death from Any Cause (Up To 30 Months)
Reported as:
Median · Months
Progression Free Survival (PFS)
Months8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² Paclitaxel
Progression Free Survival (PFS)4.14 (3.71 to 4.30)3.15 (2.83 to 4.14)
Statistical analysis
  • 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel vs Placebo + 80 mg/m² Paclitaxel · Log Rank · p = 0.0184 · Hazard ratio (hr): 0.765 · 95% CI 0.613 to 0.955
PrimaryOverall Survival (OS)

OS defined as the time from randomization to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

Time frame:
Randomization to Date of Death from Any Cause (Up To 37 Months)
Reported as:
Median · Months
Overall Survival (OS)
Months8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² Paclitaxel
Overall Survival (OS)8.71 (7.98 to 9.49)7.92 (6.31 to 9.10)
Statistical analysis
  • 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel vs Placebo + 80 mg/m² Paclitaxel · Hazard ratio (hr): 0.963 · 95% CI 0.771 to 1.203
SecondaryTime to Progression (TTP)

TTP was time from the date of randomization to the date of radiographic progression (according to RECIST v.1.1). If a participant died due to any reason without radiographic progression, TTP is censored at the last adequate tumor assessment. Target lesions: Progressive Disease (PD): At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). Non target lesions: PD: Unequivocal progression of existing lesions or the appearance of new lesion(s).

Time frame:
Randomization to the Date of the First Radiographically Documented Progressive Disease (Up To 30 Months)
Reported as:
Median · Months
Time to Progression (TTP)
Months8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² Paclitaxel
Time to Progression (TTP)4.27 (4.14 to 5.52)4.07 (2.92 to 4.17)
Statistical analysis
  • 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel vs Placebo + 80 mg/m² Paclitaxel · Hazard ratio (hr): 0.761 · 95% CI 0.598 to 0.968
SecondaryPercentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Randomization to Objective Disease Progression (Up To 30 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
Percentage of participants8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² Paclitaxel
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])26.5 (21.6 to 32.0)21.9 (15.5 to 29.5)
Statistical analysis
  • 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel vs Placebo + 80 mg/m² Paclitaxel · Odds ratio (or): 0.8 · 95% CI 0.5 to 1.2
SecondaryDuration of Objective Response (DoR)

DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Date of Objective Response to the Date of the First Radiographically Documented Progressive Disease or Death Due to Any Cause (Up To 24 Months)
Reported as:
Median · Months
Duration of Objective Response (DoR)
Months8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² Paclitaxel
Duration of Objective Response (DoR)4.34 (3.12 to 5.22)2.83 (2.56 to 4.14)
Statistical analysis
  • 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel vs Placebo + 80 mg/m² Paclitaxel · Hazard ratio (hr): 0.905 · 95% CI 0.577 to 1.421
SecondaryBest Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms. Least square (LS) mean value of changing from baseline to short-term follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\*Visit and baseline.

Time frame:
Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)
Reported as:
Least squares mean · Units on a scale
Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Units on a scale8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² Paclitaxel
Global health status5.30 ± 1.188.43 ± 1.56
Functional scale: Physical functioning1.09 ± 0.821.20 ± 1.10
Functional scale: Role functioning0.60 ± 1.131.27 ± 1.49
Functional scale: Emotional functioning5.89 ± 0.904.72 ± 1.19
Functional scale: Cognitive functioning2.87 ± 0.842.12 ± 1.11
Functional scale: Social functioning2.71 ± 1.192.98 ± 1.59
Symptom scale: Fatigue-4.20 ± 1.14-5.63 ± 1.51
Symptom scale: Nausea and vomiting-4.84 ± 0.77-3.80 ± 1.03
Symptom scale: Pain-6.89 ± 1.07-7.01 ± 1.43
Symptom scale: Dyspnea-2.18 ± 0.95-2.65 ± 1.27
Symptom scale: Insomnia-5.73 ± 1.18-7.06 ± 1.57
Symptom scale: Appetite loss-7.84 ± 1.30-10.26 ± 1.73
Symptom scale: Constipation-6.35 ± 1.11-5.41 ± 1.48
Symptom scale: Diarrhea-2.51 ± 0.86-3.03 ± 1.14
Symptom scale: Financial difficulties-8.49 ± 1.60-8.12 ± 2.13
SecondaryWorst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms. LS Mean value of changing from baseline to short-term follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\*Visit and baseline.

Time frame:
Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)
Reported as:
Least squares mean · Units on a scale
Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Units on a scale8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² Paclitaxel
Global health status-14.42 ± 1.32-9.83 ± 1.75
Functional scale: Physical functioning-14.31 ± 1.30-11.71 ± 1.73
Functional scale: Role functioning-18.46 ± 1.72-14.39 ± 2.28
Functional scale: Emotional functioning-9.80 ± 1.30-6.77 ± 1.72
Functional scale: Cognitive functioning-13.66 ± 1.40-12.08 ± 1.85
Functional scale: Social functioning-17.05 ± 1.73-16.52 ± 2.30
Symptom scale: Fatigue15.28 ± 1.3610.17 ± 1.80
Symptom scale: Nausea and vomiting8.57 ± 1.468.66 ± 1.95
Symptom scale: Pain14.01 ± 1.5010.11 ± 2.00
Symptom scale: Dyspnea16.58 ± 1.518.34 ± 2.01
Symptom scale: Insomnia14.14 ± 1.747.97 ± 2.32
Symptom scale: Appetite loss17.06 ± 1.8511.11 ± 2.46
Symptom scale: Constipation8.39 ± 1.576.58 ± 2.08
Symptom scale: Diarrhea13.41 ± 1.395.67 ± 1.85
Symptom scale: Financial difficulties10.11 ± 1.809.32 ± 2.39
SecondaryChange From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score

EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. A regression equation defines a utility value for these health states to generate an index score. The possible values for index score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state.

Time frame:
Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)
Reported as:
Mean · Units on a scale
Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score
Units on a scale8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² Paclitaxel
Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score-0.1351 ± 0.2472-0.1303 ± 0.1765
SecondaryChange From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score

EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. The EQ-5D VAS is used to record a participant's rating for his/her current health-related quality of life state on the day of questionnaire administration and is captured on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)
Reported as:
Mean · millimeter (mm)
Change From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score
millimeter (mm)8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² Paclitaxel
Change From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score-9.6 ± 20.11-8.6 ± 15.88

Adverse events

Collected over Adverse Events: Randomization Up To 26 Months; All-Cause Mortality: Randomization to Date of Death from Any Cause (Up To 37 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel246/294 (83.7%)100/293 (34.1%)287/293 (98%)
Placebo + 80 mg/m² Paclitaxel123/146 (84.2%)37/145 (25.5%)143/145 (98.6%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
Event8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² Paclitaxel
Neutrophil count decreasedInvestigations15/2933/145
Febrile neutropeniaBlood and lymphatic system disorders13/2930/145
White blood cell count decreasedInvestigations12/2932/145
PneumoniaInfections and infestations10/2935/145
Upper gastrointestinal haemorrhageGastrointestinal disorders9/2931/145
Platelet count decreasedInvestigations9/2930/145
AnaemiaBlood and lymphatic system disorders6/2934/145
VomitingGastrointestinal disorders4/2934/145
PyrexiaGeneral disorders7/2932/145
Gastrointestinal haemorrhageGastrointestinal disorders0/2933/145
Most frequent other events
Showing 10 of 58
Most frequent other events
Event8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² Paclitaxel
White blood cell count decreasedInvestigations227/293107/145
Neutrophil count decreasedInvestigations223/293102/145
AnaemiaBlood and lymphatic system disorders195/29394/145
AlopeciaSkin and subcutaneous tissue disorders83/29355/145
Aspartate aminotransferase increasedInvestigations100/29335/145
ProteinuriaRenal and urinary disorders99/29331/145
HypoalbuminaemiaMetabolism and nutrition disorders90/29331/145
Alanine aminotransferase increasedInvestigations88/29331/145
Platelet count decreasedInvestigations88/29317/145
Decreased appetiteMetabolism and nutrition disorders81/29332/145

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² PaclitaxelTotal
Mean56.00 ± 11.4956.20 ± 11.1256.10 ± 11.35
Sex: Female, Male
Sex: Female, Male(Participants)8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² PaclitaxelTotal
Female8950139
Male20596301
Race (NIH/OMB)
Race (NIH/OMB)(Participants)8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² PaclitaxelTotal
American Indian or Alaska Native000
Asian290145435
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101
More than one race314
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelPlacebo + 80 mg/m² PaclitaxelTotal
China257135392
Malaysia18725
Philippines628
Thailand13215
08

Study locations

32 sites
  • The Fifth Medical Center of PLA General Hospital
    Beijing, Beijing 100071, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
  • First hospital affiliated to Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Wu Han Tongji Hospital
    Wuhan City, Hubei 430030, China
  • Wuhan Union (Xiehe) Hospital
    Wuhan, Hubei 430022, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Jilin Province Tumor Hospital
    Chang Chun, Ji Lin 130012, China
  • Nan Jing No. 81 Hospital
    Nan Jing, Jiang Su 210002, China
  • Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med
    Nanjing, Jiangsu 210008, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210009, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai 200032, China
  • Tang Du Hospital, The Second Teaching Hospital of FMMU
    Xi'an, Shanxi 710038, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital
    Hangzhou, Zhejiang 310016, China
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, 300060, China
  • Hospital Umum Sarawak
    Kuching, Sarawak 93586, Malaysia
  • Advanced Medical & Dental Institute HUSM
    Kepala Batas, Pulau Pinang, 13200, Malaysia
  • Hospital Kuala Lumpur
    Kuala Lumpur, 50586, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • National Cancer Institute
    Wilayah Persekutuan, 62250, Malaysia
  • Cebu Doctors Hospital
    Cebu City, Cebu 6000, Philippines
  • Dr. Pablo O. Torre Memorial Hospital
    Bacolod, 6100, Philippines
  • De La Salle Health Sciences Institute
    Cavite City, 4114, Philippines
  • Rajavithi Hospital
    Bangkok, Ratchathewi District 10400, Thailand
  • King Chulalongkorn Memoiral Hospsital
    Bangkok, 10330, Thailand
  • Police General Hospital
    Bangkok, 10330, Thailand
  • Khon Kaen Hospital
    Muang, Khon Kaen, 40000, Thailand
09

References and documents

Publications

  • Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, Ba Y, Yang N, Voon PJ, Tanasanvimon S, Zhou C, Zhang WL, Shen L. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1015-1024. doi: 10.1016/S2468-1253(21)00313-7. Epub 2021 Oct 7. PubMed 34626550 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Jun 2020, 39 months.

Results were first posted in Aug 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2016
First posted
Sep 13, 2016
StartActual
Mar 2, 2017
Primary completionActual
Jun 30, 2020
CompletionActual
Apr 12, 2021
Results first posted
Aug 3, 2021
Last update
Jun 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02898077
Responsible party
Sponsor
First posted
Sep 13, 2016
Start date
Mar 2, 2017
Primary completion
Jun 30, 2020
Completion
Apr 12, 2021
Results posted
Aug 3, 2021
Last update
Jun 14, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion